' 
![]()
SCIENTIFIC SCORE
Moderately Effective
Based on 7 Researches
8.1
USERS' SCORE
Moderately Good
Based on 13 Reviews
7.9
Supplement Facts
Serving Size: About 1/4 cup (31 g)
Amount Per Serving
%DV
Calories
180
Total Fat
13 g
17%
Saturated Fat
3 g
15%
Trans Fat
0 g
Cholesterol
0 mg
0%
Sodium
0 mg
0%
Total Carbohydrate
4 g
1%
Dietary Fiber
2 g
7%
Total Sugars
0 g
Includes 0g Added Sugars
0%
Protein
11g
Vit. D
0 mcg
0%
Calcium
8 mg
0%
Iron
4 mg
20%
Potassium
243 mg
6%
Top Medical Research Studies
9
Toosendanin shows promise against PCa
Toosendanin promotes prostate cancer cell apoptosis, ferroptosis and M1 polarization via USP39-mediated PLK1 deubiquitination.
Directly examines TSN's effects
We explored the potential of Toosendanin (TSN) as a treatment for prostate cancer (PCa) in our recent investigation. By examining the effects of TSN on prostate cancer cells, specifically DU145 and LNCaP, we observed notable changes in cell behaviors. TSN treatment significantly reduced cell proliferation, migration, and invasion, while enhancing apoptosis—essentially pushing cancer cells towards a self-destructive path.
Our analysis further showed that TSN promotes a type of cell death known as ferroptosis and encourages M1 polarization, which is a process that can help recruit immune cells to fight cancer. We dug deeper into the mechanisms at play, discovering that Toosendanin lowers the levels of a protein called USP39, which is linked to the growth and stability of another protein called PLK1. This suggests that TSN might halt cancer progression by disrupting this harmful interplay.
In our studies, we also employed various techniques, including flow cytometry and western blotting, to confirm our findings. At the end of our research, we confirmed that TSN not only effectively slows down tumor growth but does so by targeting the USP39/PLK1 pathway. Altogether, these insights provide valuable information about how TSN could serve as a promising candidate in the battle against prostate cancer.
Our analysis further showed that TSN promotes a type of cell death known as ferroptosis and encourages M1 polarization, which is a process that can help recruit immune cells to fight cancer. We dug deeper into the mechanisms at play, discovering that Toosendanin lowers the levels of a protein called USP39, which is linked to the growth and stability of another protein called PLK1. This suggests that TSN might halt cancer progression by disrupting this harmful interplay.
In our studies, we also employed various techniques, including flow cytometry and western blotting, to confirm our findings. At the end of our research, we confirmed that TSN not only effectively slows down tumor growth but does so by targeting the USP39/PLK1 pathway. Altogether, these insights provide valuable information about how TSN could serve as a promising candidate in the battle against prostate cancer.
Read More
8
TOMM20 stabilizes androgen receptor
A mitochondrial outer membrane protein TOMM20 maintains protein stability of androgen receptor and regulates AR transcriptional activity in prostate cancer cells.
High relevance to prostate cancer
We explored the role of TOMM20, a protein found in the outer membranes of mitochondria, in prostate cancer (PCa). This research highlighted how TOMM20 acts as a molecular chaperone, similar to well-known proteins like HSP90 and HSP70, which help maintain the stability of the androgen receptor (AR).
Our findings showed that TOMM20 levels are significantly higher in PCa tissues and cell lines, and this increase correlates positively with AR levels. Through RNA sequencing analysis, we discovered that reducing TOMM20 led to a drop in the mRNA of AR-regulated genes. This drop was evident in the protein level of KLK3, also known as PSA, a crucial marker for prostate cancer.
Moreover, we noticed that when TOMM20 was depleted, there was a notable reduction in both the cytoplasmic and nuclear levels of AR protein, leading to its degradation via a pathway not involving heat shock proteins. This indicates that TOMM20 has a unique role in stabilizing AR and enhancing its activity, suggesting that targeting TOMM20 might be a promising strategy for PCa treatment.
Overall, our study uncovers TOMM20 as a potential biomarker for monitoring prostate cancer progression and a substantial target for therapeutic intervention.
Our findings showed that TOMM20 levels are significantly higher in PCa tissues and cell lines, and this increase correlates positively with AR levels. Through RNA sequencing analysis, we discovered that reducing TOMM20 led to a drop in the mRNA of AR-regulated genes. This drop was evident in the protein level of KLK3, also known as PSA, a crucial marker for prostate cancer.
Moreover, we noticed that when TOMM20 was depleted, there was a notable reduction in both the cytoplasmic and nuclear levels of AR protein, leading to its degradation via a pathway not involving heat shock proteins. This indicates that TOMM20 has a unique role in stabilizing AR and enhancing its activity, suggesting that targeting TOMM20 might be a promising strategy for PCa treatment.
Overall, our study uncovers TOMM20 as a potential biomarker for monitoring prostate cancer progression and a substantial target for therapeutic intervention.
Read More
8
CAIX protein enhances PCa diagnosis
The Diagnostic Value of Plasma Small Extracellular Vesicle-Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models.
High relevance for prostate cancer
We examined the potential of a specific protein, carbonic anhydrase IX (CAIX), found in small extracellular vesicles (sEVs) from plasma samples, to enhance the diagnosis of prostate cancer (PCa) and its more severe form, clinically significant prostate cancer (csPCa). Our research involved collecting plasma samples from 230 patients who had elevated levels of prostate-specific antigen (PSA) and were slated for prostate biopsy.
Through isolation and characterization of sEVs, we measured the levels of CAIX protein. By identifying independent predictors of csPCa, particularly those with a Gleason score of 7 or higher, we developed a predictive model. This model included a novel Nomogram, which proved to be a reliable tool for predicting whether patients had csPCa, thereby helping to avoid unnecessary biopsies.
The results were promising. We found that the presence of sEV-derived CAIX in the plasma correlated strongly with both PCa and csPCa diagnosis. This approach not only aids in accurate diagnosis but may also assist in guiding treatment decisions based on the prognosis indicated by CAIX levels.
Overall, our findings suggest that assessing CAIX levels could be a game-changer in the early detection and management of prostate cancer.
Through isolation and characterization of sEVs, we measured the levels of CAIX protein. By identifying independent predictors of csPCa, particularly those with a Gleason score of 7 or higher, we developed a predictive model. This model included a novel Nomogram, which proved to be a reliable tool for predicting whether patients had csPCa, thereby helping to avoid unnecessary biopsies.
The results were promising. We found that the presence of sEV-derived CAIX in the plasma correlated strongly with both PCa and csPCa diagnosis. This approach not only aids in accurate diagnosis but may also assist in guiding treatment decisions based on the prognosis indicated by CAIX levels.
Overall, our findings suggest that assessing CAIX levels could be a game-changer in the early detection and management of prostate cancer.
Read More
Most Useful Reviews
8.3
Prostate cancer protection
Rich in iron and protein, I consume a handful of pumpkin seeds between meals. They also contain zinc, selenium, kelp, and copper, which I believe help protect my prostate cancer.
Read More
8.3
Prostate support
The quality is excellent, and the taste is good. The packaging is impressive. It's ground for aiding prostate cancer.
Read More
7
Beneficial for prostate
Pumpkin seeds are recognised for their advantages, especially regarding prostate cancer. By using them consistently, I believe you'll notice a significant difference.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 7 Researches
8.1
9
Toosendanin shows promise against PCa
Toosendanin promotes prostate cancer cell apoptosis, ferroptosis and M1 polarization via USP39-mediated PLK1 deubiquitination.
Directly examines TSN's effects
We explored the potential of Toosendanin (TSN) as a treatment for prostate cancer (PCa) in our recent investigation. By examining the effects of TSN on prostate cancer cells, specifically DU145 and LNCaP, we observed notable changes in cell behaviors. TSN treatment significantly reduced cell proliferation, migration, and invasion, while enhancing apoptosis—essentially pushing cancer cells towards a self-destructive path.
Our analysis further showed that TSN promotes a type of cell death known as ferroptosis and encourages M1 polarization, which is a process that can help recruit immune cells to fight cancer. We dug deeper into the mechanisms at play, discovering that Toosendanin lowers the levels of a protein called USP39, which is linked to the growth and stability of another protein called PLK1. This suggests that TSN might halt cancer progression by disrupting this harmful interplay.
In our studies, we also employed various techniques, including flow cytometry and western blotting, to confirm our findings. At the end of our research, we confirmed that TSN not only effectively slows down tumor growth but does so by targeting the USP39/PLK1 pathway. Altogether, these insights provide valuable information about how TSN could serve as a promising candidate in the battle against prostate cancer.
Our analysis further showed that TSN promotes a type of cell death known as ferroptosis and encourages M1 polarization, which is a process that can help recruit immune cells to fight cancer. We dug deeper into the mechanisms at play, discovering that Toosendanin lowers the levels of a protein called USP39, which is linked to the growth and stability of another protein called PLK1. This suggests that TSN might halt cancer progression by disrupting this harmful interplay.
In our studies, we also employed various techniques, including flow cytometry and western blotting, to confirm our findings. At the end of our research, we confirmed that TSN not only effectively slows down tumor growth but does so by targeting the USP39/PLK1 pathway. Altogether, these insights provide valuable information about how TSN could serve as a promising candidate in the battle against prostate cancer.
Read More
9
Effects of LIG4 on prostate cancer
DNA Ligase 4 Inhibition Sensitizes Prostate Cancer to Immune Checkpoint Blockade .
Highlights complex treatment dynamics
We explored the potential of inhibiting DNA ligase IV (LIG4) as a way to enhance the treatment of prostate cancer. This study used genetically engineered models to assess how LIG4 affects tumor growth and immune responses.
By examining prostate cancer cells with both normal and reduced LIG4 levels, we discovered that inhibiting this protein led to DNA damage and cellular aging, which ultimately decreased tumor formation. Furthermore, we found that LIG4 inhibition reduced the cancer stem cell population, suggesting a less aggressive cancer behavior.
Interestingly, some prostate cancers managed to resist the effects of LIG4 inhibition by increasing levels of PD-L1, a protein that helps tumors evade the immune system. However, treatment with an anti-PD-1 antibody showed promise by increasing the infiltration of immune cells into tumors and reducing their size.
Overall, our findings indicate that targeting LIG4 could make prostate cancer more susceptible to immune checkpoint therapies, potentially improving treatment outcomes for patients.
By examining prostate cancer cells with both normal and reduced LIG4 levels, we discovered that inhibiting this protein led to DNA damage and cellular aging, which ultimately decreased tumor formation. Furthermore, we found that LIG4 inhibition reduced the cancer stem cell population, suggesting a less aggressive cancer behavior.
Interestingly, some prostate cancers managed to resist the effects of LIG4 inhibition by increasing levels of PD-L1, a protein that helps tumors evade the immune system. However, treatment with an anti-PD-1 antibody showed promise by increasing the infiltration of immune cells into tumors and reducing their size.
Overall, our findings indicate that targeting LIG4 could make prostate cancer more susceptible to immune checkpoint therapies, potentially improving treatment outcomes for patients.
Read More
8
Effective combination therapy explored
Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.
Protein treatment implications noted
We conducted a study to assess how a combination of fuzuloparib, a PARP inhibitor, and abiraterone, an androgen receptor inhibitor, can affect localized high-risk prostate cancer. In this phase 2 trial involving 35 treatment-naive men, participants received six cycles of the therapy followed by radical prostatectomy.
We aimed to measure the effectiveness of this combination therapy by evaluating two main outcomes: pathological complete response (pCR) and minimal residual disease (MRD). The results were promising, showing a combined pCR/MRD rate of 46%, indicating that nearly half of the patients had no detectable disease after treatment. Additionally, 53% of participants remained free of biochemical progression two years post-treatment.
Interestingly, we found that specific molecular alterations, particularly involving biallelic homologous recombination repair and BRCA2 genes, were tied to quicker declines in prostate-specific antigen levels, which is a key marker for prostate cancer. Genomic analyses done after treatment revealed a reduction in MYC amplification and growth markers, suggesting that the therapy effectively targeted aggressive cancer attributes.
However, it’s important to note that about 23% of patients encountered grade ≥3 adverse events, highlighting some risks associated with this treatment. Overall, this study demonstrated the potential of combining these therapies in treating prostate cancer while establishing a foundation for exploring various biomarkers that could inform future research.
We aimed to measure the effectiveness of this combination therapy by evaluating two main outcomes: pathological complete response (pCR) and minimal residual disease (MRD). The results were promising, showing a combined pCR/MRD rate of 46%, indicating that nearly half of the patients had no detectable disease after treatment. Additionally, 53% of participants remained free of biochemical progression two years post-treatment.
Interestingly, we found that specific molecular alterations, particularly involving biallelic homologous recombination repair and BRCA2 genes, were tied to quicker declines in prostate-specific antigen levels, which is a key marker for prostate cancer. Genomic analyses done after treatment revealed a reduction in MYC amplification and growth markers, suggesting that the therapy effectively targeted aggressive cancer attributes.
However, it’s important to note that about 23% of patients encountered grade ≥3 adverse events, highlighting some risks associated with this treatment. Overall, this study demonstrated the potential of combining these therapies in treating prostate cancer while establishing a foundation for exploring various biomarkers that could inform future research.
Read More
8
Integrin-targeted therapy for prostate cancer
Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth.
Relevance score indicates partial significance
This study investigates the effectiveness of a peptide, known as 5a, that targets specific proteins called αvβ6 and αvβ8 integrins. These integrins play a role in activating a powerful immune-suppressing factor called TGFβ, which is often involved in tumor growth, including prostate cancer. By binding to these integrins, peptide 5a aims to inhibit the activation of TGFβ and subsequently suppress tumor growth.
To enhance its duration in the body, peptide 5a was linked to a protein called human serum albumin (denoted as 5a-HSA). We tested this combination in laboratory settings to confirm its ability to block the interactions that promote TGFβ activation, particularly in various cancer cells and regulatory T cells, which often help tumors evade immune response.
In real-world scenarios, the study applied 5a-HSA in several mouse models of different cancers, including prostate cancer, to examine its anti-tumor effects when used alone or alongside an immune-modifying agent. The results suggest that this treatment approach could be beneficial in blocking TGFβ activation in tumors while promoting stronger immune responses, indicating a promising avenue in prostate cancer treatment.
To enhance its duration in the body, peptide 5a was linked to a protein called human serum albumin (denoted as 5a-HSA). We tested this combination in laboratory settings to confirm its ability to block the interactions that promote TGFβ activation, particularly in various cancer cells and regulatory T cells, which often help tumors evade immune response.
In real-world scenarios, the study applied 5a-HSA in several mouse models of different cancers, including prostate cancer, to examine its anti-tumor effects when used alone or alongside an immune-modifying agent. The results suggest that this treatment approach could be beneficial in blocking TGFβ activation in tumors while promoting stronger immune responses, indicating a promising avenue in prostate cancer treatment.
Read More
8
TOMM20 stabilizes androgen receptor
A mitochondrial outer membrane protein TOMM20 maintains protein stability of androgen receptor and regulates AR transcriptional activity in prostate cancer cells.
High relevance to prostate cancer
We explored the role of TOMM20, a protein found in the outer membranes of mitochondria, in prostate cancer (PCa). This research highlighted how TOMM20 acts as a molecular chaperone, similar to well-known proteins like HSP90 and HSP70, which help maintain the stability of the androgen receptor (AR).
Our findings showed that TOMM20 levels are significantly higher in PCa tissues and cell lines, and this increase correlates positively with AR levels. Through RNA sequencing analysis, we discovered that reducing TOMM20 led to a drop in the mRNA of AR-regulated genes. This drop was evident in the protein level of KLK3, also known as PSA, a crucial marker for prostate cancer.
Moreover, we noticed that when TOMM20 was depleted, there was a notable reduction in both the cytoplasmic and nuclear levels of AR protein, leading to its degradation via a pathway not involving heat shock proteins. This indicates that TOMM20 has a unique role in stabilizing AR and enhancing its activity, suggesting that targeting TOMM20 might be a promising strategy for PCa treatment.
Overall, our study uncovers TOMM20 as a potential biomarker for monitoring prostate cancer progression and a substantial target for therapeutic intervention.
Our findings showed that TOMM20 levels are significantly higher in PCa tissues and cell lines, and this increase correlates positively with AR levels. Through RNA sequencing analysis, we discovered that reducing TOMM20 led to a drop in the mRNA of AR-regulated genes. This drop was evident in the protein level of KLK3, also known as PSA, a crucial marker for prostate cancer.
Moreover, we noticed that when TOMM20 was depleted, there was a notable reduction in both the cytoplasmic and nuclear levels of AR protein, leading to its degradation via a pathway not involving heat shock proteins. This indicates that TOMM20 has a unique role in stabilizing AR and enhancing its activity, suggesting that targeting TOMM20 might be a promising strategy for PCa treatment.
Overall, our study uncovers TOMM20 as a potential biomarker for monitoring prostate cancer progression and a substantial target for therapeutic intervention.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 13 Reviews
7.9
8.8
Helpful for prostate cancer
The quality is outstanding. I gave it to my father for his prostate cancer, as he often needs to use the toilet. Although the suggested daily dose seems high, doctors advised that 5 grams daily, roughly a spoonful, is sufficient. Elderly individuals might struggle with this, so grinding it and mixing it with yogurt or a drink is advisable.
Read More
8.8
Good value prostate care
I ordered pumpkin seeds for their health benefits, particularly for prostate cancer and blood pressure. They are very reasonably priced.
8.8
Prostate cancer benefits
My husband regularly consumes these seeds to assist with his prostate cancer. They are known to be beneficial in this regard.
8.3
Prostate cancer protection
Rich in iron and protein, I consume a handful of pumpkin seeds between meals. They also contain zinc, selenium, kelp, and copper, which I believe help protect my prostate cancer.
8.3
Prostate support
The quality is excellent, and the taste is good. The packaging is impressive. It's ground for aiding prostate cancer.
